Moberg Pharma AB (MOB) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

28.47 k

Shareholding (Mar 2017)

FII

0.23%

Held by 1 FIIs

DII

99.77%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

The company declared negative results in Dec'24 after very positive results in Sep'24

NET PROFIT(9M) At SEK -253.47 MM has Grown at -1,392.06%
RAW MATERIAL COST(Y) Grown by 29.18% (YoY)

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 475 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.35

Return on Equity

-38.08%

Price to Book

0.70

Revenue and Profits:

Net Sales:

4 Million

(Quarterly Results - Jun 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

10.17%

6 Months

-41.21%

1 Year

-63.95%

2 Years

-30.07%

3 Years

-30.43%

4 Years

-75.29%

5 Years

-89.69%

Moberg Pharma AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

68.29%

EBIT Growth (5y)

-254.35%

EBIT to Interest (avg)

-81.88

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.39

Sales to Capital Employed (avg)

0.01

Tax Ratio

20.49%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.23%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.58

EV to EBIT

-0.44

EV to EBITDA

-0.44

EV to Capital Employed

0.34

EV to Sales

11.57

PEG Ratio

Dividend Yield

ROCE (Latest)

-76.27%

ROE (Latest)

-37.48%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2017

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.23%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -7.69% vs 290.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -164.29% vs 98.85% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.60",
          "val2": "3.90",
          "chgp": "-7.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.30",
          "val2": "-4.30",
          "chgp": "-116.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.40",
          "val2": "-2.80",
          "chgp": "-164.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,696.90%",
          "val2": "-1,225.40%",
          "chgp": "-147.15%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1,109.00% vs -34.39% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.60",
          "val2": "-26.40",
          "chgp": "10.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-255.10",
          "val2": "-21.10",
          "chgp": "-1,109.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-33,114.60%",
          "val2": "0.00%",
          "chgp": "-3,311.46%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

3.60

3.90

-7.69%

Operating Profit (PBDIT) excl Other Income

-9.30

-4.30

-116.28%

Interest

0.00

0.10

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-7.40

-2.80

-164.29%

Operating Profit Margin (Excl OI)

-2,696.90%

-1,225.40%

-147.15%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -7.69% vs 290.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -164.29% vs 98.85% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

9.80

0.00

Operating Profit (PBDIT) excl Other Income

-23.60

-26.40

10.61%

Interest

0.20

0.30

-33.33%

Exceptional Items

0.00

Consolidate Net Profit

-255.10

-21.10

-1,109.00%

Operating Profit Margin (Excl OI)

-33,114.60%

0.00%

-3,311.46%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -1,109.00% vs -34.39% in Dec 2023

All Annual Results

Company CV

About Moberg Pharma AB

Moberg Pharma AB

Pharmaceuticals & Biotechnology

Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.

Company Coordinates

Company Details

Gustavslundsvagen 42, 5 tr. , BROMMA None : 167 51

Tel: 46 8 52230700

http://www.mobergpharma.se/

Registrar Details